Boundless Bio reports Q1 EPS (71c) vs ($12.27) last year

“Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio (BOLD). “We look forward to providing a clinical data update on our BBI-355 program later this year. Additionally, we expect to nominate a development candidate for our novel Kinesin program by mid-year, with plans to submit an IND in the first half of 2026.”